enGene Therapeutics (ENGN) vs Molecular Partners (MOLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Molecular Partners (MOLN) has outperformed enGene Therapeutics (ENGN) over the past year, losing 37.5% versus a loss of 75.0%. enGene Therapeutics is the larger company by market cap ($116.6 million vs $96.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENGN | MOLN |
|---|---|---|
| Share price | $1.74 | $2.53 |
| Market cap | $116.61M | $96.80M |
| 1-day change | -1.14% | -5.25% |
| YTD return | -80.73% | -42.07% |
| 1-year return | -75.00% | -37.50% |
| 5-year return | — | -77.87% |
| EPS (TTM) | $-2.07 | $-1.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-117.30M | — |
| 52-week high | $12.25 | $5.36 |
| 52-week low | $1.40 | $2.52 |
| Distance from 52-week high | -85.80% | -52.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.55% | +295.64% |
| Average volume | 1.12M | 1.63K |
| Shares outstanding | 67.02M | 38.34M |
| Employees | 81 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MOLN has outperformed ENGN by 37.5 percentage points over the past year.
About enGene Therapeutics
ENGN stock →enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Molecular Partners
MOLN stock →Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
ENGN vs MOLN FAQ
Which is bigger, enGene Therapeutics or Molecular Partners?
enGene Therapeutics (ENGN) is larger, with a market capitalization of $116.61M compared with $96.80M for Molecular Partners (MOLN).
Which stock has performed better over the past year, ENGN or MOLN?
MOLN returned -37.50% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.
Are enGene Therapeutics and Molecular Partners in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.